540 participants
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-05
- Start Date:
- 2025-08-26
- Completion:
- 2028-04-30
Conditions
- PIK3CA Mutation
- HER2- Negative Breast Cancer
- Hormone Receptor Positive Tumor
- Breast Cancer
- Metastatic Breast Cancer
- Advanced Breast Cancer
Interventions
- DRUG
No Results Yet